MA34609B1 - Composé de cyclopropane - Google Patents
Composé de cyclopropaneInfo
- Publication number
- MA34609B1 MA34609B1 MA35823A MA35823A MA34609B1 MA 34609 B1 MA34609 B1 MA 34609B1 MA 35823 A MA35823 A MA 35823A MA 35823 A MA35823 A MA 35823A MA 34609 B1 MA34609 B1 MA 34609B1
- Authority
- MA
- Morocco
- Prior art keywords
- hydrogen atom
- atom
- independently
- antagonist activity
- orexin receptor
- Prior art date
Links
- -1 CYCLOPROPANE COMPOUND Chemical class 0.000 title 1
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 abstract 3
- 108050000742 Orexin Receptor Proteins 0.000 abstract 2
- 102000008834 Orexin receptor Human genes 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 206010022437 insomnia Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen(.) Chemical compound [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
)LA PRÉSENTE INVENTION CONCERNE UN COMPOSÉ REPRÉSENTÉ PAR LA FORMULE (A) [DANS LAQUELLE Q REPRÉSENTE -CH- OU UN ATOME D'AZOTE ; R1A ET R1B REPRÉSENTENT INDÉPENDAMMENT UN GROUPE ALKYLE EN C1 À C6 OU ANALOGUES ; R1C REPRÉSENTE UN ATOME D'HYDROGÈNE OU ANALOGUES ; R2A, R2B, R2C ET R2D REPRÉSENTENT INDÉPENDAMMENT UN ATOME D'HYDROGÈNE, UN ATOME D'HALOGÈNE OU ANALOGUES ; R3A, R3B ET R3C REPRÉSENTENT INDÉPENDAMMENT UN ATOME D'HYDROGÈNE, UN ATOME D'HALOGÈNE OU ANALOGUES ; ET R3D REPRÉSENTE UN ATOME D'HYDROGÈNE OU ANALOGUES] OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, POSSÉDANT UNE ACTIVITÉ ANTAGONISTE SUR UN RÉCEPTEUR DE L'OREXINE ET POUVANT DONC ÊTRE UTILISÉ EN TANT QU'AGENT THÉRAPEUTIQUE POUR DES TROUBLES DU SOMMEIL, TELS QUE L'INSOMNIE, SUR LESQUELS L'ACTIVITÉ ANTAGONISTE SUR UN RÉCEPTEUR DE L'OREXINE EST EFFICACE.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38534210P | 2010-09-22 | 2010-09-22 | |
| JP2010211629 | 2010-09-22 | ||
| PCT/JP2011/071325 WO2012039371A1 (fr) | 2010-09-22 | 2011-09-20 | Composé de cyclopropane |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA34609B1 true MA34609B1 (fr) | 2013-10-02 |
Family
ID=45873858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA35823A MA34609B1 (fr) | 2010-09-22 | 2011-09-20 | Composé de cyclopropane |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8268848B2 (fr) |
| EP (1) | EP2626350B1 (fr) |
| JP (1) | JP4944286B1 (fr) |
| KR (1) | KR101458007B1 (fr) |
| CN (1) | CN103153963B (fr) |
| AR (1) | AR083060A1 (fr) |
| AU (1) | AU2011304285B2 (fr) |
| BR (1) | BR112013006594B1 (fr) |
| CA (1) | CA2811895C (fr) |
| CL (1) | CL2013000784A1 (fr) |
| DK (1) | DK2626350T3 (fr) |
| ES (1) | ES2540851T3 (fr) |
| IL (1) | IL225437A (fr) |
| JO (1) | JO2990B1 (fr) |
| MA (1) | MA34609B1 (fr) |
| MX (1) | MX2013003218A (fr) |
| MY (1) | MY160969A (fr) |
| NZ (1) | NZ609313A (fr) |
| PE (1) | PE20131162A1 (fr) |
| PL (1) | PL2626350T3 (fr) |
| PT (1) | PT2626350E (fr) |
| RS (1) | RS54101B1 (fr) |
| RU (1) | RU2571414C2 (fr) |
| SG (1) | SG188585A1 (fr) |
| SI (1) | SI2626350T1 (fr) |
| TW (1) | TWI516484B (fr) |
| UA (1) | UA108510C2 (fr) |
| WO (1) | WO2012039371A1 (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014019909B1 (pt) | 2012-02-17 | 2020-01-28 | Eisai R&D Man Co Ltd | processo para produção de compostos úteis como antagonistas do receptor de orexina-2 |
| US9663513B2 (en) | 2012-11-20 | 2017-05-30 | Merck Sharp & Dohme Corp. | Pyrimidine PDE10 inhibitors |
| US10065930B2 (en) * | 2014-08-06 | 2018-09-04 | Eisai R&D Management Co., Ltd. | Method for producing pyrimidine-1-ol compound, and intermediate thereof |
| CA2964504C (fr) * | 2014-10-23 | 2022-08-23 | Eisai R&D Management Co., Ltd. | Forme de dose orale comprenant un derive de cyclopropanecarboxamide pourutilisation dans le traitement de l'insomnie |
| WO2017073710A1 (fr) | 2015-10-29 | 2017-05-04 | 東レ株式会社 | Dérivé morphinane et usage médical associé |
| CN109640998A (zh) | 2016-05-12 | 2019-04-16 | 卫材研究发展管理有限公司 | 治疗昼夜节律性睡眠障碍的方法 |
| WO2019024845A1 (fr) * | 2017-08-01 | 2019-02-07 | 苏州科睿思制药有限公司 | Forme cristalline d'antagoniste du récepteur de l'orexine, procédé de préparation associé et utilisation correspondante |
| KR20220008804A (ko) | 2019-05-15 | 2022-01-21 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 오렉신-2 수용체 길항제의 제조에 유용한 방법 및 화합물, 및 약간의 불순물을 갖는 렘보렉산트 |
| CA3144067A1 (fr) * | 2019-06-26 | 2020-12-30 | Eisai R&D Management Co., Ltd. | Lemborexant pour le traitement de problemes de sommeil |
| WO2021119223A1 (fr) * | 2019-12-11 | 2021-06-17 | Teva Czech Industries S.R.O. | Forme à l'état solide du lemborexant |
| CA3165481A1 (fr) | 2019-12-20 | 2021-06-24 | Eisai R&D Management Co., Ltd. | Utilisation de lemborexant pour le traitement de l'insomnie |
| CA3164198A1 (fr) | 2020-01-16 | 2021-07-22 | Eisai R&D Management Co., Ltd. | Substance medicamenteuse de lemborexant et composition medicinale comprenant celle-ci |
| WO2021205648A1 (fr) * | 2020-04-10 | 2021-10-14 | 国立大学法人東海国立大学機構 | Procédé objectif d'évaluation du sommeil pour un patient souffrant d'un trouble mental |
| JP2024527024A (ja) | 2021-07-26 | 2024-07-19 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 神経変性疾患に伴う不規則睡眠・覚醒リズム障害及び概日リズム睡眠障害を治療する方法における使用のためのレンボレキサント |
| CN118843622A (zh) * | 2022-03-25 | 2024-10-25 | 浙江华海药业股份有限公司 | 莱博雷生及其中间体化合物的制备方法 |
| WO2023178693A1 (fr) * | 2022-03-25 | 2023-09-28 | 浙江华海药业股份有限公司 | Procédé de préparation de lemborexant et procédé de préparation d'intermédiaire de lemborexant |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06328057A (ja) | 1993-05-26 | 1994-11-29 | Sanyo Electric Co Ltd | 厨芥処理装置 |
| CA2220036A1 (fr) | 1995-05-05 | 1996-11-07 | Human Genome Sciences, Inc. | Recepteur de neuropeptides humain |
| NZ335910A (en) * | 1996-12-10 | 2000-11-24 | Bristol Myers Squibb Co | Benzodioxole, benzofuran, dihydrobenzofuran and benzodioxane melatonergic agents useful in treating sleep disorders and circadian rhthym related disorders |
| US6001963A (en) | 1996-12-17 | 1999-12-14 | Smithkline Beecham Corporation | Ligands of the neuropeptide receptor HFGAN72 |
| US6309854B1 (en) | 1996-12-17 | 2001-10-30 | Smithkline Beecham Corporation | Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72 |
| US6020157A (en) | 1997-04-30 | 2000-02-01 | Smithkline Beecham Corporation | Polynucleotides encoding HFGAN72X receptor |
| US5935814A (en) | 1997-04-30 | 1999-08-10 | Smithkline Beecham Corporation | Polynucleotides encoding HFGAN72Y receptor |
| US6166193A (en) | 1997-07-25 | 2000-12-26 | Board Of Regents, University Of Texas System | Polynucleotides encoding MY1 receptor |
| US7763638B2 (en) | 2004-03-01 | 2010-07-27 | Actelion Pharmaceuticals Ltd. | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives |
| BRPI0515571A (pt) * | 2004-09-23 | 2008-07-29 | Pfizer Prod Inc | agonistas de receptor de trombopoetina |
| CN101155792A (zh) * | 2005-04-12 | 2008-04-02 | 默克公司 | 氨基丙氧基苯基增食欲素受体拮抗剂 |
| JP2008538361A (ja) * | 2005-04-12 | 2008-10-23 | メルク エンド カムパニー インコーポレーテッド | アミドプロポキシフェニルオレキシン受容体アンタゴニスト |
| JP2006328057A (ja) * | 2005-04-25 | 2006-12-07 | Eisai R & D Management Co Ltd | 抗不安薬及びそのスクリーニング方法 |
| JP4582722B2 (ja) | 2006-03-15 | 2010-11-17 | アクテリオン ファーマシューティカルズ リミテッド | 記憶機能を向上させるテトラヒドロイソキノリン誘導体 |
| WO2007129188A1 (fr) | 2006-05-10 | 2007-11-15 | Pfizer Japan Inc. | Composé de cyclopropanecarboxamide |
| JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
| CA2662538A1 (fr) | 2006-09-11 | 2008-03-20 | Glaxo Group Limited | Composes azabicycliques en tant qu'inhibiteurs de reabsorption de monoamines |
| JP2010504957A (ja) * | 2006-09-29 | 2010-02-18 | アクテリオン ファーマシューティカルズ リミテッド | ３−アザ−ビシクロ［３．１．０］ヘキサン誘導体 |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| TW200833328A (en) * | 2006-12-28 | 2008-08-16 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo[3.1.0]hexane derivatives |
| RU2010115747A (ru) | 2007-09-21 | 2011-10-27 | Санофи-Авентис (Fr) | (циклопропилфенил)фенилоксаламиды, способ их получения и их применения в качестве лекарственного средства |
| PE20091010A1 (es) | 2007-10-10 | 2009-08-08 | Actelion Pharmaceuticals Ltd | Derivados de tetrahidroquinolina |
| MX2011005800A (es) * | 2008-12-02 | 2011-06-20 | Glaxo Group Ltd | Derivados de n{[(1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4. 1.0]hept-4-il]metil}-2-heteroarilamina y sus usos. |
| US20120165339A1 (en) * | 2010-12-22 | 2012-06-28 | Eisai R&D Management Co., Ltd. | Cyclopropane derivatives |
-
2011
- 2011-09-20 RS RS20150418A patent/RS54101B1/en unknown
- 2011-09-20 WO PCT/JP2011/071325 patent/WO2012039371A1/fr active Application Filing
- 2011-09-20 MX MX2013003218A patent/MX2013003218A/es active IP Right Grant
- 2011-09-20 PE PE2013000532A patent/PE20131162A1/es active IP Right Grant
- 2011-09-20 MY MYPI2013000954A patent/MY160969A/en unknown
- 2011-09-20 EP EP11826816.8A patent/EP2626350B1/fr active Active
- 2011-09-20 SI SI201130507T patent/SI2626350T1/sl unknown
- 2011-09-20 PT PT118268168T patent/PT2626350E/pt unknown
- 2011-09-20 JP JP2012500752A patent/JP4944286B1/ja active Active
- 2011-09-20 KR KR1020137009631A patent/KR101458007B1/ko active IP Right Grant
- 2011-09-20 AU AU2011304285A patent/AU2011304285B2/en active Active
- 2011-09-20 BR BR112013006594-0A patent/BR112013006594B1/pt active IP Right Grant
- 2011-09-20 AR ARP110103428A patent/AR083060A1/es active IP Right Grant
- 2011-09-20 ES ES11826816.8T patent/ES2540851T3/es active Active
- 2011-09-20 CA CA2811895A patent/CA2811895C/fr active Active
- 2011-09-20 SG SG2013019880A patent/SG188585A1/en unknown
- 2011-09-20 TW TW100133754A patent/TWI516484B/zh active
- 2011-09-20 JO JOP/2011/0289A patent/JO2990B1/ar active
- 2011-09-20 MA MA35823A patent/MA34609B1/fr unknown
- 2011-09-20 UA UAA201304939A patent/UA108510C2/ru unknown
- 2011-09-20 CN CN201180045556.7A patent/CN103153963B/zh active Active
- 2011-09-20 NZ NZ609313A patent/NZ609313A/en unknown
- 2011-09-20 PL PL11826816T patent/PL2626350T3/pl unknown
- 2011-09-20 RU RU2013117464/04A patent/RU2571414C2/ru active
- 2011-09-20 US US13/237,205 patent/US8268848B2/en active Active
- 2011-09-20 DK DK11826816.8T patent/DK2626350T3/en active
-
2013
- 2013-03-21 CL CL2013000784A patent/CL2013000784A1/es unknown
- 2013-03-21 IL IL225437A patent/IL225437A/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA34609B1 (fr) | Composé de cyclopropane | |
| MX2010004232A (es) | Compuesto de indolina de pirimidilo. | |
| DE602006003432D1 (de) | Latoren des androgenrezeptors | |
| DE602006012322D1 (de) | Als androgen-rezeptor-modulatoren verwendbare tetrahydrocarbazol-derivate | |
| BR112015020545A2 (pt) | derivado de tetraidroimidazo[1,5-d][1,4]oxazepina | |
| NO20080865L (no) | Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer | |
| MX2020010151A (es) | Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn. | |
| RU2502730C2 (ru) | Сульфонамидные соединения и их применение | |
| PE20081609A1 (es) | Compuestos carboxamida y su uso como inhibidores de calpaina | |
| EA201100698A1 (ru) | Производные тиенотриазолодиазепина, активные в отношении апо а1 | |
| MA31118B1 (fr) | Procede de preparation d'un derive de benzimidazole | |
| PE20080234A1 (es) | Combinacion antiepileptica que comprende derivados de benzoheteroarilsulfamidas | |
| MA38275A1 (fr) | Hétérocycles azotés saturés et n-acylés potentialisant l'activité d'un antibiotique actif contre les mycobactéries | |
| MA32563B1 (fr) | Dabigatran pour cathétérisme cardiaque de chirurgie percutanée | |
| BR112014009927A2 (pt) | "derivado de azol, composição farmacêutica que o compreende e uso do mesmo" | |
| MA33618B1 (fr) | Agent thérapeutique destiné aux troubles de l'humeur | |
| MA35893B1 (fr) | Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7 | |
| EA022994B1 (ru) | Способ подавления толерантности к опиоидному анальгетику | |
| MA38679B1 (fr) | Modulateurs du récepteur de cxcr7 | |
| MA38659B1 (fr) | Dérivés éthynyle comme antagonistes du récepteur métabotrope du glutamate | |
| MX2013002956A (es) | Arilsulfonamidas para el tratamiento de enfermedades del sistema nervioso central. | |
| MA33619B1 (fr) | Agent thérapeutique pour des troubles de l'anxiété | |
| AR053122A1 (es) | Monohidrato de di-s-camsilato de 5((2r,5s)-5-metil-4-propilmorfolin-2-il)piridin-2-amina, agonista de dopamina | |
| AR089112A1 (es) | Asociacion entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un antagonista de los receptores nmda y las composiciones farmaceuticas que la contienen | |
| NO20080285L (no) | Alfa-(aryl- eller heteroarylmetyl)-beta-piperidinopropionsyreforbindelser som ORL-1-reseptorantagonist |